Uploaded November 2026 | Updated November 2026, 4 days ago
Biopharmaceutical company UCB recently shared findings from a mixed-methods study examining the experiences and unmet needs of people living with ocular myasthenia gravis (oMG). The findings were presented at the 2026 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and Myasthenia Gravis Foundation of America (MGFA) Scientific Session.
Anna Kole, Global Patient Engagement Lead for Myasthenia Gravis at UCB, discusses the findings and explains how patient perspectives could improve clinical research and care.
Biopharmaceutical company UCB recently shared findings from a mixed-methods study examining the experiences and unmet needs of people living with ocular myasthenia gravis (oMG). The findings were presented at the 2026 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and Myasthenia Gravis Foundation of America (MGFA) Scientific Session.
Anna Kole, Global Patient Engagement Lead for Myasthenia Gravis at UCB, discusses the findings and explains how patient perspectives could improve clinical research and care.










